Immunovant (NASDAQ:IMVT) Stock Falls 6.8% – What’s Next?

Immunovant, Inc. (NASDAQ:IMVT) was down 6.8% during trading on Wednesday. The stock traded as low as $35.34 and last traded at $34.7420. Approximately 701,117 shares were traded during mid-day trading, a decline of 53% from the average daily volume of 1,500,243 shares. The stock had previously closed at $37.29.

Key Immunovant News

Here are the key news stories impacting Immunovant this week:

• Positive Sentiment: IMVT-1402 showed positive trends across multiple measures, with greater IgG reductions associated with better clinical outcomes. The drug also produced a favorable safety and tolerability profile consistent with earlier studies. Immunovant Announces Topline Results from Proof-of-Concept Study
• Positive Sentiment: Immunovant said all other clinical development timelines remain on track, helping preserve potential value from its broader autoimmune and inflammatory disease pipeline. Roivant reports top-line data from IMVT-1402 CLE trial
• Neutral Sentiment: A market-data update reported zero shares sold short as of September 24, implying a zero-day short-interest ratio. The figure appears unusual relative to reported trading activity and may have limited significance for investors until confirmed.
• Negative Sentiment: The CLE proof-of-concept study failed to achieve statistical significance on its primary endpoint, the change in CLASI-A score at Week 12. Immunovant concluded the results did not meet its internal threshold for continued development and will halt IMVT-1402’s CLE program. IMVT Ends Cutaneous Lupus Erythematosus Program
• Negative Sentiment: The trial miss and program termination reduce the addressable opportunity for IMVT-1402 and undermine confidence in its efficacy, which are the primary reasons for recent pressure on Immunovant (IMVT).

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immunovant in a research note on Monday, July 6th. Citigroup restated a “positive” rating on shares of Immunovant in a research note on Thursday. UBS Group reaffirmed a “buy” rating on shares of Immunovant in a research report on Wednesday. Sanford C. Bernstein upgraded Immunovant to a “hold” rating in a research note on Wednesday, July 29th. Finally, HC Wainwright reissued a “buy” rating on shares of Immunovant in a research note on Thursday. Eight research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Immunovant has an average rating of “Moderate Buy” and an average price target of $44.00.

Immunovant Stock Performance

The firm has a market capitalization of $7.02 billion, a PE ratio of -12.06 and a beta of 0.81. The company’s 50-day moving average price is $39.89 and its 200-day moving average price is $33.89.

Immunovant (NASDAQ:IMVT) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.75) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.12). The business had revenue of $7.09 million during the quarter, compared to the consensus estimate of $7.09 million. During the same quarter in the previous year, the company posted ($0.71) EPS. As a group, analysts anticipate that Immunovant, Inc. will post -2.96 earnings per share for the current year.

Insider Buying and Selling at Immunovant

In related news, CTO Jay Stout sold 3,487 shares of the company’s stock in a transaction that occurred on Wednesday, July 8th. The stock was sold at an average price of $39.55, for a total value of $137,910.85. Following the completion of the transaction, the chief technology officer directly owned 208,198 shares of the company’s stock, valued at $8,234,230.90. This represents a 1.65% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Eric Venker sold 3,092 shares of the stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $38.48, for a total transaction of $118,980.16. Following the completion of the transaction, the chief executive officer directly owned 254,280 shares in the company, valued at $9,784,694.40. This trade represents a 1.20% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders have sold 11,321 shares of company stock worth $450,017. 1.90% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Immunovant

A number of large investors have recently modified their holdings of IMVT. BlackRock Inc. purchased a new stake in shares of Immunovant in the second quarter valued at approximately $276,680,000. Jennison Associates LLC increased its holdings in shares of Immunovant by 356.4% in the 1st quarter. Jennison Associates LLC now owns 3,196,705 shares of the company’s stock valued at $79,406,000 after purchasing an additional 2,496,241 shares in the last quarter. Two Seas Capital LP acquired a new stake in shares of Immunovant in the second quarter valued at about $121,312,000. ADAR1 Capital Management LLC boosted its holdings in Immunovant by 8.0% during the first quarter. ADAR1 Capital Management LLC now owns 2,679,010 shares of the company’s stock worth $66,547,000 after buying an additional 198,042 shares in the last quarter. Finally, Perceptive Advisors LLC increased its holdings in Immunovant by 25.6% in the fourth quarter. Perceptive Advisors LLC now owns 1,994,890 shares of the company’s stock valued at $50,710,000 after buying an additional 407,000 shares in the last quarter. 47.08% of the stock is owned by hedge funds and other institutional investors.

About Immunovant

Immunovant, Inc (NASDAQ: IMVT) is a clinical-stage biopharmaceutical company developing therapies for patients with immune-mediated diseases. The company focuses on conditions in which disease-causing antibodies, or immunoglobulin G (IgG), play a central role, including autoimmune and inflammatory disorders.

Immunovant’s lead product candidate is batoclimab, an investigational fully human monoclonal antibody designed to block the neonatal Fc receptor (FcRn). By inhibiting FcRn, batoclimab is intended to reduce circulating IgG antibodies that can contribute to autoimmune disease.